AstraZeneca acquired a Montreal-based biologics manufacturing facility from DSM Biologics. The facility, occupying 66,000 sq. ft., will be used to manufacture antibody drug candidates for clinical trials and will serve the whole of the AstraZeneca group.
Work to recommission the facility is expected to begin immediately, and the company plans to commence full scale production in 2009.